These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 22395687)
41. The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective. Saynor ZL; Barker AR; Oades PJ; Williams CA Pediatr Phys Ther; 2014; 26(4):454-61. PubMed ID: 25251804 [TBL] [Abstract][Full Text] [Related]
42. A new model for drug development using a multi-stakeholder consortium. Hall AK BMJ; 2014 Mar; 348():g1850. PubMed ID: 24603569 [No Abstract] [Full Text] [Related]
43. New drugs 2013, Part I. Hussar DA Nursing; 2013 Feb; 43(2):36-46; quiz 47-8. PubMed ID: 23302940 [No Abstract] [Full Text] [Related]
46. Straight talk with... María Blasco. Interview by Elie Dolgin. Blasco M Nat Med; 2011 Aug; 17(8):909. PubMed ID: 21818075 [No Abstract] [Full Text] [Related]
47. The Louis and Artur Lucian Award in Cardiovascular Diseases at McGill University. Genest J; Hébert TE; Martin J Circ Res; 2016 Oct; 119(9):975-977. PubMed ID: 27737939 [No Abstract] [Full Text] [Related]
52. Excitement mounts for first disease-modifying cystic fibrosis drugs. Opar A Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393 [No Abstract] [Full Text] [Related]
53. FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label. Ratner M Nat Biotechnol; 2017 Jul; 35(7):606. PubMed ID: 28700545 [No Abstract] [Full Text] [Related]
54. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Kaiser J Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790 [No Abstract] [Full Text] [Related]
55. Straight talk with... Robert Beall. Interviewed by Elie Dolgin. Beall R Nat Med; 2012 Mar; 18(3):335. PubMed ID: 22395687 [No Abstract] [Full Text] [Related]